SG11202101827RA - N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors - Google Patents
N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitorsInfo
- Publication number
- SG11202101827RA SG11202101827RA SG11202101827RA SG11202101827RA SG11202101827RA SG 11202101827R A SG11202101827R A SG 11202101827RA SG 11202101827R A SG11202101827R A SG 11202101827RA SG 11202101827R A SG11202101827R A SG 11202101827RA SG 11202101827R A SG11202101827R A SG 11202101827RA
- Authority
- SG
- Singapore
- Prior art keywords
- dioxocyclobutenylamino
- picolinamides
- hydroxy
- substituted
- useful
- Prior art date
Links
- -1 N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862734486P | 2018-09-21 | 2018-09-21 | |
PCT/IB2019/057856 WO2020058869A1 (en) | 2018-09-21 | 2019-09-18 | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202101827RA true SG11202101827RA (en) | 2021-04-29 |
Family
ID=68051869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202101827RA SG11202101827RA (en) | 2018-09-21 | 2019-09-18 | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors |
Country Status (29)
Country | Link |
---|---|
US (2) | US10975065B2 (en) |
EP (1) | EP3852879A1 (en) |
JP (1) | JP6989729B2 (en) |
KR (2) | KR102615234B1 (en) |
CN (2) | CN116874466A (en) |
AR (1) | AR116464A1 (en) |
AU (1) | AU2019344107B2 (en) |
BR (1) | BR112021003956A2 (en) |
CA (1) | CA3055805A1 (en) |
CL (1) | CL2021000683A1 (en) |
CO (1) | CO2021003391A2 (en) |
CR (1) | CR20210146A (en) |
CU (1) | CU20210016A7 (en) |
DO (1) | DOP2021000045A (en) |
EA (1) | EA202190586A1 (en) |
EC (1) | ECSP21018584A (en) |
GE (1) | GEP20237476B (en) |
IL (1) | IL281634A (en) |
MA (1) | MA53643A (en) |
MX (1) | MX2021003318A (en) |
NI (1) | NI202100012A (en) |
NZ (1) | NZ773473A (en) |
PE (1) | PE20211070A1 (en) |
PH (1) | PH12021550554A1 (en) |
SG (1) | SG11202101827RA (en) |
TW (1) | TWI754172B (en) |
UY (1) | UY38379A (en) |
WO (1) | WO2020058869A1 (en) |
ZA (1) | ZA202101169B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2021003318A (en) * | 2018-09-21 | 2021-05-14 | Pfizer | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors. |
EP4143179A1 (en) | 2020-04-30 | 2023-03-08 | Idorsia Pharmaceuticals Ltd | Azetidin-3-ylmethanol derivatives as ccr6 receptor modulators |
WO2023057548A1 (en) | 2021-10-07 | 2023-04-13 | Idorsia Pharmaceuticals Ltd | Ccr6 receptor modulators |
TW202325278A (en) | 2021-10-26 | 2023-07-01 | 瑞士商愛杜西亞製藥有限公司 | Ccr6 receptor modulators |
CA3236396A1 (en) | 2021-10-28 | 2023-05-04 | Oliver Allemann | Ccr6 receptor modulators |
CN116162081A (en) * | 2022-12-13 | 2023-05-26 | 药康众拓(江苏)医药科技有限公司 | Deuterated pyridine amide CCR6 inhibitor medicine and application thereof |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5354763A (en) | 1993-11-17 | 1994-10-11 | American Home Products Corporation | Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones |
US5466712A (en) | 1994-11-04 | 1995-11-14 | American Home Products Corporation | Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones |
DK0796243T3 (en) | 1994-11-16 | 1999-09-13 | American Home Prod | Diaminocyclobuten-3,4-diones |
DE69837903T2 (en) | 1997-08-11 | 2008-02-14 | Pfizer Products Inc., Groton | Solid pharmaceutical dispersions with increased bioavailability |
US6495576B2 (en) | 2001-02-07 | 2002-12-17 | Abbott Laboratories | Aminal diones as potassium channel openers |
DK1818325T3 (en) | 2001-04-16 | 2010-05-31 | Schering Corp | 3,4-di-substituted cyclobutene-1,2-dione as CXC-chemokine receptor ligands |
MXPA04009127A (en) | 2002-03-18 | 2005-01-25 | Schering Corp | Combination treatments for chemokine-mediated diseases. |
AU2003288922A1 (en) * | 2002-10-09 | 2004-05-04 | Pharmacopeia, Inc. | Thiadiazoledioxides and thiadiazoleoxides as cxc- and cc-chemokine receptor ligands |
CN101203509B (en) | 2005-02-16 | 2013-05-08 | 默沙东公司 | Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity |
DK2010509T3 (en) | 2006-03-31 | 2014-10-06 | Janssen Pharmaceutica Nv | 3,4-DIAMINO-3-CYCLOBUTEN-1,2-DION DERIVATIVES AS POTASSIUM CHANNEL OPENERS |
EP2021316A1 (en) | 2006-05-26 | 2009-02-11 | Abbott Laboratories | Inhibitors of polo-like kinases |
AU2007269572A1 (en) | 2006-07-07 | 2008-01-10 | Pharmacopeia, Inc. | 3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
CN103641823A (en) | 2007-04-30 | 2014-03-19 | Abbvie公司 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme |
AU2008258588B2 (en) | 2007-06-06 | 2011-11-10 | Novartis Ag | Anti -inflammatory substituted cyclobutenedione compounds |
WO2009005802A1 (en) | 2007-07-05 | 2009-01-08 | Schering Corporation | Process for controlled crystal size in 1,2-substituted 3,4-dioxo-1-cyclobutene compounds |
WO2009012375A2 (en) | 2007-07-19 | 2009-01-22 | Wyeth | Squarate kinase inhibitors |
JP2010534669A (en) | 2007-07-24 | 2010-11-11 | ブリストル−マイヤーズ スクイブ カンパニー | Acyclic derivatives as modulators of chemokine receptor activity |
WO2009015166A1 (en) | 2007-07-24 | 2009-01-29 | Bristol-Myers Squibb Company | Piperidine derivatives as modulators of chemokine receptor activity |
MX2010006089A (en) | 2007-12-04 | 2010-09-22 | Schering Corp | Methods of treating copd. |
UA103198C2 (en) | 2008-08-04 | 2013-09-25 | Новартис Аг | Squaramide derivatives as cxcr2 antagonists |
WO2010063802A1 (en) | 2008-12-05 | 2010-06-10 | Novartis Ag | 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists |
WO2010131145A1 (en) * | 2009-05-12 | 2010-11-18 | Pfizer Limited | Cyclobutenedione derivatives |
WO2011029046A1 (en) | 2009-09-04 | 2011-03-10 | Biogen Idec Ma Inc. | Bruton's tyrosine kinase inhibitors |
EP2498780B1 (en) | 2009-11-12 | 2016-09-07 | F.Hoffmann-La Roche Ag | N-9-substituted purine compounds, compositions and methods of use |
FR2961695B1 (en) | 2010-06-29 | 2012-07-06 | Galderma Res & Dev | USE OF COMPOUNDS IN THE TREATMENT OR PREVENTION OF SKIN DISORDERS |
US8648070B2 (en) | 2010-12-17 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments |
US8648118B2 (en) | 2010-12-17 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Bicyclic ring system substituted amide functionalised phenols as medicaments |
EP2751086A4 (en) | 2011-08-30 | 2015-09-16 | Chdi Foundation Inc | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
FR2981934B1 (en) * | 2011-10-28 | 2013-12-20 | Galderma Res & Dev | NOVEL DI-SUBSTITUTED DIAMINO-3,4-CYCLOBUTENE-3-DIONE-1,2 COMPOUNDS USEFUL IN THE TREATMENT OF CHEMOKINE MEDIATED PATHOLOGIES. |
FR2981936B1 (en) | 2011-10-28 | 2013-12-20 | Galderma Res & Dev | NOVEL DI-SUBSTITUTED DIAMINO-3,4-CYCLOBUTENE-3-DIONE-1,2 COMPOUNDS USEFUL IN THE TREATMENT OF CHEMOKINE MEDIATED PATHOLOGIES. |
FR2981935B1 (en) | 2011-10-28 | 2015-08-07 | Galderma Res & Dev | NOVEL DI-SUBSTITUTED DIAMINO-3,4-CYCLOBUTENE-3-DIONE-1,2 COMPOUNDS USEFUL IN THE TREATMENT OF CHEMOKINE MEDIATED PATHOLOGIES. |
AU2013265266A1 (en) | 2012-05-23 | 2015-01-15 | Stemergie Biotechnology Sa | Inhibitors of the activity of complex (III) of the mitochondrial electron transport chain and use thereof |
EA028509B1 (en) | 2012-12-19 | 2017-11-30 | Новартис Аг | Autotaxin inhibitors, pharmaceutical compositions and combinations comprising same and use thereof in the treatment of diseases and conditions mediated by autotaxin |
JP2016509602A (en) | 2013-01-25 | 2016-03-31 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Squaric acid derivatives for the treatment of hepatitis C |
US10138256B2 (en) | 2013-03-15 | 2018-11-27 | Celgene Car Llc | MK2 inhibitors and uses thereof |
FR3030515B1 (en) | 2014-12-23 | 2017-01-20 | Galderma Res & Dev | NOVEL ANTAGONIST COMPOUNDS FOR CHEMOKINE CXCR1 AND CXCR2 RECEPTORS AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED PATHOLOGIES |
TWI734715B (en) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | Modulators of chemokine receptors |
TWI724056B (en) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Inhibitors of cxcr2 |
US10660909B2 (en) * | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
MX2021003318A (en) * | 2018-09-21 | 2021-05-14 | Pfizer | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors. |
-
2019
- 2019-09-18 MX MX2021003318A patent/MX2021003318A/en unknown
- 2019-09-18 NZ NZ773473A patent/NZ773473A/en unknown
- 2019-09-18 CA CA3055805A patent/CA3055805A1/en active Pending
- 2019-09-18 CN CN202310857008.9A patent/CN116874466A/en active Pending
- 2019-09-18 JP JP2021514571A patent/JP6989729B2/en active Active
- 2019-09-18 KR KR1020217007932A patent/KR102615234B1/en active IP Right Grant
- 2019-09-18 CN CN201980058547.8A patent/CN112672791B/en active Active
- 2019-09-18 CU CU2021000016A patent/CU20210016A7/en unknown
- 2019-09-18 EA EA202190586A patent/EA202190586A1/en unknown
- 2019-09-18 AU AU2019344107A patent/AU2019344107B2/en active Active
- 2019-09-18 CR CR20210146A patent/CR20210146A/en unknown
- 2019-09-18 PE PE2021000331A patent/PE20211070A1/en unknown
- 2019-09-18 MA MA053643A patent/MA53643A/en unknown
- 2019-09-18 WO PCT/IB2019/057856 patent/WO2020058869A1/en active Application Filing
- 2019-09-18 KR KR1020237043152A patent/KR20230175326A/en active Application Filing
- 2019-09-18 GE GEAP201915588A patent/GEP20237476B/en unknown
- 2019-09-18 EP EP19773556.6A patent/EP3852879A1/en active Pending
- 2019-09-18 BR BR112021003956-2A patent/BR112021003956A2/en unknown
- 2019-09-18 SG SG11202101827RA patent/SG11202101827RA/en unknown
- 2019-09-19 UY UY0001038379A patent/UY38379A/en not_active Application Discontinuation
- 2019-09-20 AR ARP190102673A patent/AR116464A1/en unknown
- 2019-09-20 US US16/576,997 patent/US10975065B2/en active Active
- 2019-09-20 TW TW108134010A patent/TWI754172B/en active
-
2021
- 2021-02-22 ZA ZA2021/01169A patent/ZA202101169B/en unknown
- 2021-02-24 NI NI202100012A patent/NI202100012A/en unknown
- 2021-03-05 US US17/192,968 patent/US11708360B2/en active Active
- 2021-03-12 PH PH12021550554A patent/PH12021550554A1/en unknown
- 2021-03-16 EC ECSENADI202118584A patent/ECSP21018584A/en unknown
- 2021-03-16 CO CONC2021/0003391A patent/CO2021003391A2/en unknown
- 2021-03-18 IL IL281634A patent/IL281634A/en unknown
- 2021-03-19 CL CL2021000683A patent/CL2021000683A1/en unknown
- 2021-03-19 DO DO2021000045A patent/DOP2021000045A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283639A (en) | Kif18a inhibitors | |
IL277006A (en) | Cd73 inhibitors | |
IL269196A (en) | Novel inhibitors | |
IL304348A (en) | Cd73 inhibitors | |
IL268614A (en) | Aminotriazolopyridines as kinase inhibitors | |
IL276269A (en) | Aminopyrrolotriazines as kinase inhibitors | |
IL281634A (en) | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors | |
IL274207B (en) | Aminoimidazopyridazines as kinase inhibitors | |
GB201819126D0 (en) | Inhibitor compounds | |
IL276013A (en) | Pi4kiiibeta inhibitors | |
IL274036A (en) | Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as p2x3 inhibitors | |
IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
GB201812462D0 (en) | Inhibitors | |
GB201804439D0 (en) | Dopamin-b-hydroxylase inhibitors | |
GB201908044D0 (en) | Dopamine-B-Hydroxylase inhibitors | |
GB201905476D0 (en) | MAPA4K4 Inhibitors | |
GB201809939D0 (en) | Eastase inhibitor | |
GB201819136D0 (en) | Inhibitor compounds | |
GB201806131D0 (en) | Inhibitor compounds | |
GB201806130D0 (en) | Inhibitor compounds |